- Report
- May 2024
- 130 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- November 2023
- 353 Pages
Global
From €8646EUR$9,500USD£7,412GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2503EUR$2,750USD£2,146GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Letrozole is a type of breast cancer drug used to treat postmenopausal women with hormone receptor-positive, early-stage breast cancer. It is a type of aromatase inhibitor, which works by blocking the production of estrogen in the body. This helps to slow or stop the growth of certain types of breast cancer cells that need estrogen to grow. Letrozole is usually taken once a day, with or without food. Common side effects include hot flashes, joint pain, and nausea.
Letrozole is a widely used breast cancer drug, and is often prescribed in combination with other treatments such as radiation or chemotherapy. It is also used to reduce the risk of breast cancer recurrence in postmenopausal women who have already been treated with other medications.
Some companies in the Letrozole market include Novartis, Pfizer, and AstraZeneca. Show Less Read more